Hepatitis Drug Development Pipeline Review, 2017

Published: August 2017
No. of Pages: 209
Price: Single User: US $ 3995  US $ 3396 Corporate User: US $ 11985  US $ 9588
    ReportsandReports

This report is available at 15% Discount for Single User License and 20% Discount for Corporate Users License till 01 September 2017. To avail discount please contact at +1-888-391-5441 / sales@reportsandreports.com.


Summary

Hepatitis is a contagious viral infection affecting the liver, which may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting. The predisposing factors of hepatitis typically include dialysis, organ transplant and blood transfusion and theoffspring of an infected mother also has high chances of contracting the disease.

Owing to differences in prevalence, hepatitis A and D have far smaller pipelines than hepatitis B and C; there are a total of seven products in development for hepatitis A, by four companies and two academic institutions. Beijing Minhai Biotechnology are fielding two pipeline products in this area, while all other companies are fielding only one. In hepatitis D there are a total of 12 products in development, by nine companies and one academic institution. Key companies operating in this pipeline space include EigerBioPharmaceuticalsand Replicor.

Many of the companies who are actively fielding products in the larger two hepatitis subtypes are simultaneously developing products for both.

There are a total of 182 products in development for hepatitis B, by 110 companies and 14 academic institutions. Key companies operating in this pipeline space include Arbutus Biopharma, F. Hoffmann-La Roche, Johnson & Johnson, Assembly Biosciences, Gilead Sciences and InstitutoButantan. There are a total of 199 products in development for hepatitis C, by 92 companies and 34 academic institutions. Key companies operating in this pipeline space include Merck & Co, AbbVie, Johnson & Johnson, Gilead Sciences, Cocrystal Pharma, Bristol-Myers Squibb and F. Hoffmann-La Roche.

While in hepatitis A, B and D, viral surface antigens and interferons are commonly targeted, a far wider range of proteins, including non-structural proteins, are the most common targets in hepatitis C.

The report "Hepatitis Drug Development Pipeline Review, 2017", provides an overview of the hepatitis pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hepatitis A, B, C and D, and features dormant and discontinued projects.

Scope

  • Which companies are the most active within the pipeline for hepatitis therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of hepatitis?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.

Published By: GBI Research
Product Code: GBI Research1631


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: